What Terrapeutics Pharma does

Terrapeutics Pharma is a privately-held Israeli biotech founded in 2019 and headquartered in Jerusalem, operating with 1-10 employees. The company has built a drug discovery platform that screens naturally evolved molecular scaffolds produced by soil microorganisms against therapeutic targets that conventional synthetic chemistry-based discovery cannot reach. The platform specifically targets classes historically considered 'undruggable,' including protein-protein interactions, non-steroidal transcription factors, and nucleic acid complexes, with current pipeline focus on RAS inhibitors for cancer and novel antibiotics for infectious disease.

The company's core technology exploits what it estimates is 99.9% of nature's therapeutic potential that current discovery methodologies fail to access, leveraging scaffolds developed through 4 billion years of microbial evolution. Validation is anchored by a co-development agreement with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Germany for joint work on antibiotics and RAS inhibitors, and a partnership with HekaBio K.K. to bring the platform to the Japanese market. Selection into Illumina Accelerator's fifth global funding cycle provides additional third-party endorsement of the underlying science.

Terrapeutics operates a B2B licensing and partnership-driven model, monetizing through co-development agreements and platform licensing to pharmaceutical and biotechnology counterparties rather than through direct product sales. The company has raised approximately $1.39M across two Peregrine Ventures rounds in 2024 and 2025, supplemented by an in-kind Illumina Accelerator investment. Pricing is not publicly disclosed and appears to be negotiated per partnership or per license. As of the available data, no commercial licensing transactions have been announced, and the company remains in pre-revenue platform validation phase.

Name

Terrapeutics Pharma

Legal name

Terrapeutics

Website

https://terrapeuticspharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Terrapeutics Pharma is an Israel-based biotech using soil microorganism-derived molecular scaffolds to discover drugs against 'undruggable' targets such as RAS-driven cancers and antibiotic-resistant infections, licensing its platform to pharmaceutical partners through co-development agreements.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Drug discovery platform
• Nature-derived therapeutics
• RAS inhibitor discovery
• Soil microorganism screening
• Undruggable target discovery

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Discovery Platform Licensing: Revenue model appears to be licensing the proprietary drug discovery platform technology to pharmaceutical companies. The company discovers and develops molecules for challenging targets (RAS inhibitors, antibiotics) and likely licenses these candidates or the platform technology to larger pharma companies for further development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Terrapeutics Pharma operates a proprietary drug discovery platform that screens molecular scaffolds produced by soil microorganisms to identify therapeutic candidates against targets considered "undruggable" by conventional synthetic chemistry approaches. Current therapeutic focus areas include RAS inhibitors for cancer and novel antibiotics for infectious diseases, with candidates advanced through licensing and co-development agreements with pharmaceutical partners.

Product overview

Terrapeutics Pharma operates as a single-platform drug discovery company offering its proprietary drug discovery platform. This unified platform enables the screening of nature-derived therapeutic molecules against challenging and previously 'undruggable' drug targets. The company's current therapeutic focus areas include RAS inhibitors for cancer treatment and infectious diseases, with plans to expand to additional undruggable targets.

Differentiator

Problem solved

Functional benefit

Products and services

• Terrapeutics Drug Discovery Platform

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• HekaBio K.K.coreStrategic or Co-development PartnerTerrapeutics Pharma partnered with HekaBio K.K. to bring their revolutionary drug discovery platform to Japan. This partnership enables geographic expansion into the Japanese pharmaceutical market.
• HIPS (Helmholtz Institute for Pharmaceutical Research Saarland)coreStrategic or Co-development PartnerTerrapeutics signed a cooperation agreement with HIPS for the joint development of novel bioactive compounds including antibiotics and RAS inhibitors for the treatment of incurable cancers. This represents a major co-development partnership for pipeline advancement.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Insitro: Insitro combines machine learning with high-throughput biology to discover therapeutics for challenging diseases. It is a broader incumbent whose partnership-driven business model closely parallels Terrapeutics' GTM motion, although its biology-first platform differs in modality.
• Schrödinger Inc. Schrödinger provides computational drug discovery software and services that increasingly enable screening of novel chemical spaces. It competes with nature-derived approaches by offering in silico alternatives for difficult targets and partners with many of the same pharma companies.
• Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics, representing a broader incumbent addressing the same 'undruggable' target problem from a synthetic-biology angle. It competes for pharma partnership dollars focused on novel target classes.
• Recursion Pharmaceuticals: Recursion applies AI-driven high-throughput biology to drug discovery, competing for partnerships with pharma seeking novel approaches to challenging targets. While broader in scope, it competes for the same licensing and co-development mindshare among large pharma partners.
• Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors, directly addressing the same RAS target class that Terrapeutics highlights as a current focus. It is a broader incumbent setting the competitive bar in the same therapeutic area.

Emerging players

• Atomwise: Atomwise applies AI to small-molecule discovery against challenging protein targets, with a partnership-heavy model analogous to Terrapeutics'. It is an emerging player in the 'undruggable target' space where both compete for the same pharma partner mindshare.
• Antheia: Antheia uses synthetic biology to produce plant-derived and opioid pharmaceuticals from engineered microbes. It is an emerging player adjacent to Terrapeutics in leveraging biological platforms to access hard-to-make therapeutic molecules.
• Federation Bio: Federation Bio engineers microbiome-derived therapeutics, with overlapping interest in microbial chemistry and synthetic biology approaches. It is an emerging player in the broader nature-derived therapeutic space with partial overlap in undruggable target strategies.

Direct peers

• Hexagon Bio: Hexagon Bio is a US-based drug discovery company that mines fungal genomes for novel therapeutics, making it the closest direct peer to Terrapeutics' soil-microorganism screening approach. Both target nature-derived chemical diversity to address difficult drug targets.
• Lodo Therapeutics: Lodo Therapeutics (acquired by Zymergen) applied microbial metagenomics and machine learning to identify novel drug candidates from soil bacteria, directly mirroring Terrapeutics' nature-derived discovery thesis. It represents an early comparable for the soil-microbe drug discovery business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/feed/update/urn:li:activity:7209085043007229952/?commentUrn=urn%3Ali%3Acomment%3A%28ugcPost%3A7209085040662634499%2C7209107779880407041%29&dashCommentUrn=urn%3Ali%3Acomment%3A%28ugcPost%3A7209085040662634499%2C7209107779880407041%29&actorCompanyId=80039518

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terrapeutics Pharma